What Over 4.1 Million Treatment Plans Reveal About Patient Follow-Through
Insights from more than 4.1 million initial supplement treatment plans highlight when patients purchase recommendations, how much of a plan they purchase, and how providers can help them get started.
At a glance
- Most eventual first purchases happened within the first week. Among plans with at least one recommended product purchased within 90 days, 78.7% had reached their first purchase within seven days, and 93.7% within 30 days. The pattern suggests that the initial plan conversation and early follow-up are important opportunities to reinforce understanding and address barriers.
- Purchasing often involved either none or all of a plan's products. Among five-product plans, 42.0% had no matched purchase of any of the five recommended products, while 33.4% had all five purchased. The remaining plans had some but not all of the recommended products purchased. Since patients may be evaluating the plan as a whole rather than individual product recommendations, this pattern reinforces the importance of clearly explaining which recommendations are priorities, which are alternatives, and what the patient should start first.
- There was no simple “fewer is better” rule. A higher share of product recommendations was purchased in moderately sized (2–7 product) plans than in either single-product or larger plans. The analysis does not establish an ideal number of supplements to recommend.
You have reviewed the patient's concerns, discussed your assessment, and sent a supplement treatment plan. One important question remains: which recommendations will the patient actually act on?
Perhaps they will order everything. Perhaps they already have some products at home, will buy them elsewhere, or are unsure where to start. An order history or notification can help you understand what happened, but it cannot tell the whole story.
We examined 4,175,989 initial treatment plans across 82,051 Fullscript practice accounts to see which recommended products were purchased through Fullscript over the subsequent 90 days. This captures one early step in treatment plan follow-through; it does not tell us whether the products were actually taken or whether health improved.
Ready to start delivering better patient care?
Join 135,000 healthcare providers who rely on Fullscript to dispense top-quality supplements and labs to their patients.
Finding 1: Most first purchases happened early
By 90 days, 49.5% of plans we analyzed had at least one recommended product purchased through Fullscript. All recorded supplement recommendations were purchased for 36.4% of plans, while some but not all were purchased for 13.1%. No purchase of any recommended product was observed for the remaining 50.5%.

When purchasing occurred, it usually happened early. Among the approximately 2.07 million plans with at least one recommended-product purchase during the 90-day period:
For nearly four out of five plans with a purchase by 90 days, that first purchase happened within the first week. These percentages describe plans that eventually had a purchase, not all plans in the study.


Why it matters
The early purchasing pattern makes the initial plan conversation and early follow-up worth focusing on. Before the patient leaves the appointment, as well as soon after the visit, make sure they understand what they are starting, why it was recommended, and what the next step is.
Broader medication adherence guidelines, and our earlier work on the topic of treatment adherence, emphasize understanding patients' concerns and practical barriers. (3) A patient-centered conversation can help surface issues such as cost, uncertainty about the recommendation, or confusion about how to get started.
Explain the plan during the appointment and reinforce it in writing. Where starting promptly fits the clinical plan, agree on a concrete next step, such as obtaining the recommended products during the coming week, or deciding when and where they will obtain them. A brief check of understanding can help: “Which products will you start with, and how will you take them?” AHRQ recommends asking patients to explain the plan in their own words, checking the clarity of the explanation rather than testing the patient. (2)
Practical takeaway: use the first days after sending the plan as an opportunity to reinforce understanding and identify barriers early, while recognizing that this study did not test whether a particular follow-up strategy improves purchasing.
Finding 2: Patients may respond to the plan as a whole
It can be tempting to provide several recommendations and assume patients will choose the ones they are ready to start, or know the differences between certain products. The purchasing pattern suggests that this assumption deserves a closer look.
Among 305,501 plans containing five recommended products, 42.0% had zero products purchased within 90 days, while a relatively similar 33.4% had all five products purchased. These were the two most common outcomes, not an in-between purchase of one to four products.
To see whether this pattern could occur simply because each product had an independent chance of being purchased, we compared the observed results with a simple reference model. In that model, partial purchases of two, three, or four products would have been much more common. Instead, the real-world purchases clustered much more strongly at none or all five, as shown in the figure below.
One explanation is that patients first decide whether to act on the plan as a whole. Shared circumstances, such as affordability, understanding of the plan, or readiness to begin, could also explain the pattern. The study did not measure patients' reasons, and it is possible the purchases occurred across several orders.

Why it matters
A provider may see a treatment plan as a set of priorities, alternatives, and recommendations intended for different stages of care. A patient may instead see one list of products they are expected to purchase together, increasing the possibility of overwhelm or price aversion.
Make priorities explicit. If two products are alternatives, say so. If the plan is phased, explain what starts now and what can wait. If cost limits what is feasible, discuss which recommendations are most important rather than leaving the patient to infer priorities from the product list.
The written plan should reinforce that conversation. Fullscript allows providers to specify dosage, frequency, duration, additional instructions, and a reason for taking each product. Review those fields so they reflect the plan you discussed.
Practical takeaway: make it obvious which recommendations are essential now, which are alternatives, and which can be introduced later. If the goal is not necessarily for every patient to purchase everything at once, help them to understand what you have agreed they should start.
Finding 3: Plan size does not tell the whole story
The relationship between plan size and purchasing was not a straight line. In other words, fewer recommendations did not always correspond to a higher purchase rate.
To examine this further, we looked at ordering of individual product recommendations rather than whole plans. Across plans of each size, what percentage of the recommended products had a recorded purchase?

For example, in the two-to-seven group, approximately 47 out of every 100 product recommendations were purchased. This does not mean that 46.6% of those plans were purchased in full. The largest plans were uncommon, representing fewer than 0.5% of included plans.

For plans with 2–7 recommendations, the matched recommendation purchase rate was 1.17 times that for single-recommendation plans, 1.07 times that for 8–20, and 3.74 times that for 21+. These boundaries should not be interpreted as evidence of an ideal treatment-plan size. The broader groups in the table were chosen after viewing that pattern, not set in advance as clinically meaningful categories.
Why it matters
The finding does not mean every plan should contain two to seven products, and it does not justify adding clinically unnecessary recommendations simply to target a particular plan size.
It does suggest that providers should not assume a single-product plan will necessarily be easier for a patient to act on. If the clinical assessment identifies other appropriate recommendations, or if the patient’s current supplement list contains opportunity for better quality options, there is no reason to avoid including them simply because the plan would contain more than one product.
Plan size alone cannot tell us whether recommendations are clinically indicated, affordable, or easy to follow. The study did not account for plan cost, patients’ reasons for seeking care, products already being used, or how priorities were communicated.
Practical takeaway: build the plan around the patient’s actual clinical needs and ability to act on it, rather than aiming for a particular number of products. Ask whether each recommendation is justified, whether the patient understands why it is there, and whether the proposed starting plan is realistic for them.
Helping patients put the plan into action
The findings offer a starting point for two conversations: explaining the plan before the patient acts on it, and reviewing what actually happened afterward.
Before the patient leaves: Explain the recommendation, product, and source
For each recommendation, and ideally before the patient leaves the appointment, make sure they understand:
- Why it is part of the plan: Explain how the recommendation fits their care and what you are hoping it will address.
- Why you selected that particular product: Discuss relevant features such as ingredient form, amount per serving, combination of ingredients, or suitability for the patient.
- Why you recommend a particular source: If you recommend obtaining the product through Fullscript, explain the sourcing and quality-assurance processes behind that recommendation.
- What alternatives are acceptable: If the patient prefers another source or a lower-cost option, explain what features should be matched and invite them to review substitutions with you.
If a patient chooses a different product, compare its label with the recommended product rather than relying on the product name alone. Check the listed ingredients and amounts per serving, then consider other relevant differences such as ingredient form or formulation. The Supplement Facts label identifies ingredients and amounts per serving and can help when reviewing an alternative. (4)
Fullscript’s quality program includes brand vetting, verification of third-party good manufacturing practice certification, and additional testing of selected products. Products are sourced directly from brands and stored in Fullscript’s NSF-certified facilities. This analysis did not compare the quality of products sold through Fullscript with products sold elsewhere.
At follow-up, ask what actually happened
An order history is a starting point for a conversation, not a substitute for one. AHRQ's guidance recommends reviewing the medicines and supplements patients actually use and confirming how they obtain and take them. (1) At each follow-up, consider asking:
- What did you obtain, and from where? Ask about Fullscript orders, purchases elsewhere, products already at home, and substitutions. Review the bottle or label when something differs from the recommendation.
- What have you actually started? Confirm the amount, frequency, and start date, along with anything stopped or changed and any unwanted effects. Encourage patients to keep their medication and supplement list up to date using Fullscript’s Currently Taking feature.
- What made it difficult to get started or continue? Ask about cost, unclear instructions, uncertainty about priorities, concerns about the recommendation, or difficulty accessing the plan.
The purpose is to understand the patient’s experience, not to grade their compliance. Someone who purchased the same product elsewhere needs a different conversation from someone who could not afford the plan, misunderstood the recommendation, or stopped because of an unwanted effect. The National Institute for Health and Care Excellence (NICE) recommends a nonjudgmental discussion of the reasons for nonadherence and support tailored to the specific difficulty. (3)
Record what the patient reports taking and revise the plan where appropriate. The clinically useful question is not simply “Did you order?” but “What were you able to start, and what do we need to work through together?”
Why this research matters
This analysis examines a step in care between making a recommendation and assessing its effects. It shows when initial purchasing happened, how much of a recorded plan was purchased, and why an order alone cannot tell us whether the plan was put into practice.
For providers, the opportunity is to connect the recommendation with a clear next step and then ask what happened. Purchasing data can inform that conversation, but understanding the patient's experience requires follow-up.
Future analyses can explore how recommendations, purchases, patient-reported use, and repeat purchases fit together. For now, the central lesson is simpler: sending a plan and knowing what the patient started are two different parts of care.
How to interpret these findings
- Purchasing is not the same as use or benefit. The study did not measure whether products were taken as directed or whether patients improved. Purchases outside Fullscript were not observed.
- These were selected initial plans. The findings should not be treated as benchmarks for every patient, provider, or follow-up plan. A patient profile is an account record, not necessarily one unique person.
- The comparisons do not establish causation. Cost, clinical needs, communication, and other factors were not accounted for together. The results do not establish an optimal plan size or prove that a particular communication strategy improves purchasing.
- Plans can change. The recommendations counted may reflect additions, cancellations, or replacements made during the 90-day period, and the available data do not always allow the exact timing of those changes to be reconstructed. Purchasing “all” therefore means all products counted under the study's definitions, not necessarily the exact regimen originally presented to the patient.
Research methods
Study design and cohort
We examined de-identified records from Fullscript's US platform for 4,175,989 treatment plans across 82,051 Fullscript practice accounts and 97,896 provider. Plans became available between January 1, 2023 and June 23, 2026, allowing 90 days of observation before the September 21, 2026 cutoff. Plans from providers categorized as Veterinary Medicine were excluded.
For each patient profile at a practice, we selected the first eligible supplement plan in that period and excluded profiles with earlier recorded plan or purchase activity at the same practice since January 2021. “Initial” means the first plan meeting these study criteria, not necessarily someone's first clinical visit or first-ever supplement recommendation.
We checked whether products recorded on each plan appeared in completed Fullscript purchases linked to that plan within 90 days. We compared plans with none, some, or all recommended products purchased, examined purchase timing, and looked at differences by the number of products recommended.
The absence of a Fullscript purchase does not mean the patient did not follow the plan. They may have purchased the same products elsewhere, chosen an alternative, or already owned them. This analysis could not establish those reasons.
Product matching and timing
Variants belonging to the same verified parent product were combined. For example, two different flavors of the same omega–3 liquid product were counted as one recommendation. Exact product-code matching was used when no verified parent was available. Multiple units or repeat purchases counted only once per recommendation. Directly linked purchases within 12 hours before recorded plan availability were included in the first day to allow for timestamp discrepancies.
Analysis and supporting checks
These were unadjusted observational comparisons, with plan-size groups chosen after examining the data. We also repeated the analyses across several subgroups and alternative definitions, including patient age and recorded sex, provider type, ingredient family, plan source, study year, product-matching rules, and changes to recommendations. The main patterns were generally consistent across these checks, including across the five most common provider groups (nurse practitioners, medical doctors, naturopathic doctors, nutrition-related providers, and chiropractors), study years, and plans created directly in Fullscript versus connected software, although the percentages varied between groups. These checks support interpretation but do not remove the limitations of the analysis.
Learn more
Clinical Insights Pulse explores real-world patterns across the Fullscript network, combining de-identified data with clinical interpretation to identify useful questions for everyday practice.
Explore Fullscript's quality program and treatment-plan instructions for resources to support conversations about product selection, sourcing, and how to get started.
About the data behind the clinical insights pulse
Clinical Insights Pulse uses de-identified data prepared in accordance with HIPAA requirements. Researchers work only with aggregated datasets, not individual records. All findings describe aggregated clinical patterns, not individual outcomes. Each publication is reviewed before release.
These analyses are conducted in accordance with Fullscript's applicable Terms of Service, Labs Terms of Service, and Privacy Statement, which describe how de-identified information may be used to improve our platform, advance research, and generate clinical insights.
Ready to start delivering better patient care?
Join 135,000 healthcare providers who rely on Fullscript to dispense top-quality supplements and labs to their patients.

